Ontwikkeling van vaccins tegen malaria

Five years ago, the very first malaria vaccine, RTS,S/AS01, received a positive evaluation by the European Medicines Agency. Although this vaccine does not achieve the WHO’s target of 75% protection, it does set the standard for all new vaccine candidates. In this article, we describe the progress made in the development of several second-generation malaria vaccines, an area where Dutch research has made major contributions. These include vaccines with live, attenuated Plasmodium falciparum sporozoites and transmission-blocking vaccines. Thanks in part to Dutch contributions, the development of vaccines against malaria has recently made significant progress on the way to the finish line: a vaccine that provides protection to the most vulnerable population - young children in Africa.

Conflict of interest and financial support: none declared.